<DOC>
	<DOCNO>NCT00595829</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability JAK2 inhibitor XL019 administer orally adults Polycythemia Vera .</brief_summary>
	<brief_title>A Phase 1 Study XL019 Adults With Polycythemia Vera</brief_title>
	<detailed_description />
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<criteria>The subject diagnosis polycythemia vera ( PV ) , fail , intolerant , standard therapy refuse take standard medication . The subject ≥18 year old . The subject Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 . The subject adequate organ function . Subjects received phlebotomy due PV must document phlebotomy history 12 week prior enrollment . The subject capability understanding informed consent document sign informed consent document . Sexually active subject ( male female ) must use medically acceptable method contraception course study . Female subject childbearing potential must negative pregnancy test screening . The subject diagnosis malignancy evidence malignancey 2 year prior screen study ( except nonmelanoma skin cancer situ carcinoma cervix ) . The subject receive treatment PV within 14 day prior first dose XL019 The subject uncontrolled intercurrent illness include , limited , ongoing active infection , hypertension , symptomatic congestive heart failure , unstable angina pectoris , myocardial infarction within 3 month , cardiac arrhythmia . The subject pregnant breastfeeding . The subject know positive human immunodeficiency virus ( HIV ) . The subject unable unwilling abide study protocol cooperate fully investigator designee .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Polycythemia Vera</keyword>
	<keyword>PV</keyword>
</DOC>